Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07211542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 8, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Primary endpoint revised Enrollment target: 70 to 75v4 Show 1 more changeShow less
    • Enrollment target: 70 to 75

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2025 to Nov 7, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Nov 2025 to Nov 7, 2025
    • Site details revised
  4. Enrollment target: 20 to 70 Primary completion date: Apr 2026 to Sep 2026 · Completion date: Sep 2026 to Feb 2027 · Secondary endpoints revised (12) · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Apr 2026 to Sep 2026
    • Completion date: Sep 2026 to Feb 2027
    • Secondary endpoints revised (12)
    • Study arms: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Trial Details
NCT Number NCT07211542
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate-to-severe Atopic Dermatitis
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov